Randomized phase III study of first-line selpercatinib versus chemotherapy and pembrolizumab in RET fusion-positive NSCLC
Refereed conference paper presented and published in conference proceedings
Full Text
Digital Object Identifier (DOI) DOI for CUHK Users View Full-text in Publisher Website |
Altmetrics Information
.
Other information
All Author(s) ListLoong H.H.F., Goto K., Solomon B.J., Park K., Perol M., Arriola E., Novello S., Cheng Y., Ardizzoni A., Mak M., Santini F.C., Elamin Y.Y., Drilon A., Wolf J., Han B., Han H., Uh M., Puri T., Ilaria V., Zhou C.
Name of ConferenceAnnual Meeting of the European-Society-for-Medical-Oncology (ESMO)
Start Date of Conference20/10/2023
End Date of Conference24/10/2023
Place of ConferenceBarcelona
Country/Region of ConferenceSpain
Proceedings TitleAnnals of Oncology
Detailed descriptionAnnual Meeting of the European-Society-for-Medical-Oncology (ESMO), Barcelona, SPAIN, OCT 20-24, 2023
Year2023
Month10
Volume Number34
Issue NumberSuppl 2
PublisherELSEVIER
PagesS1303 - S1303
ISSN0923-7534
LanguagesEnglish-United States
